Company Overview
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Recent Developments
- May 2025 Revenue of $5.31M (-1.9% YoY); net profit $-4.97M.
- Trailing 12 Months Year-on-year growth — revenue +16.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.58% |
| 1 Year: | 16.80% |
Stock Price Performance
| 1 Year: | -22.77% |
| 6 Months: | +6.85% |
| 3 Months: | +13.04% |
| 1 Month: | +45.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)77.54 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 33.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMRA Biomerica, Inc. PHARMA | 2.34 | -1.80 | $10.74M | 0.00% | -122.16% | -112.10% | 0.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Feb 2013 | Aug 2013 | Nov 2013 | Feb 2014 | Aug 2014 | Nov 2014 | Feb 2015 | Aug 2015 | Nov 2015 | Feb 2016 | Aug 2016 | Nov 2016 | Feb 2017 | Aug 2017 | Nov 2017 | Feb 2018 | Aug 2018 | Nov 2018 | Feb 2019 | Aug 2019 | Nov 2019 | Feb 2020 | Aug 2020 | Nov 2020 | Feb 2021 | Aug 2021 | Nov 2021 | Feb 2022 | Aug 2022 | Nov 2022 | Feb 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | Aug 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26M | 1.19M | 1.60M | 1.18M | 1.14M | 1.37M | 3.63M | 1.26M | 4.65M | 7.66M | 1.64M | 1.48M | 1.11M | 1.71M | 1.57M | 1.02M | 1.81M | 1.64M | 1.12M | 1.38M | 1.21M | 987.00K |
| Gross Profit | 445.38K | 260.29K | 255.64K | 578.56K | 309.91K | 307.24K | 458.83K | 421.42K | 412.04K | 344.52K | 576.96K | 556.68K | 449.43K | 514.57K | 506.19K | 465.37K | 337.22K | 408.06K | 365.92K | 367.30K | 468.87K | 211.98K | 118.09K | 308.72K | -73.43K | -88.97K | 771.76K | 1.67M | -55.00K | 352.00K | 120.00K | 412.00K | 325.00K | -149.00K | 289.00K | 437.00K | 19.00K | 424.00K | 51.00K | -44.00K |
| Operating Income | -63.33K | -173.77K | -247.50K | 32.62K | -224.11K | -249.87K | -135.54K | -76.23K | -209.77K | -269.11K | -65.63K | -219.54K | -317.72K | -226.03K | -288.74K | -322.85K | -454.79K | -485.94K | -707.25K | -509.56K | -489.74K | -914.88K | -1.90M | -1.71M | -2.17M | -1.54M | -1.13M | -107.50K | -2.07M | -1.67M | -1.65M | -1.23M | -1.61M | -2.00M | -1.37M | -993.00K | -1.21M | -1.12M | -1.37M | -1.30M |
| Net Income | -35.61K | -167.71K | -243.36K | 26.54K | -219.27K | -238.03K | -117.19K | -72.33K | -66.77K | -135.00K | -55.42K | -202.89K | -304.14K | -207.06K | -268.66K | -322.49K | -451.74K | -477.24K | -678.75K | -506.30K | -485.26K | -860.93K | -1.89M | -1.72M | -2.12M | -1.54M | -1.13M | -104.17K | -2.07M | -1.63M | -1.65M | -1.13M | -1.51M | -1.92M | -1.32M | -950.00K | -1.16M | 2.00K | -1.32M | -1.31M |
| Diluted EPS | -0.01 | -0.02 | -0.03 | 0.00 | -0.03 | -0.03 | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | -0.03 | -0.04 | -0.05 | -0.05 | -0.07 | -0.05 | -0.05 | -0.09 | -0.16 | -0.15 | -0.18 | -0.12 | -0.09 | -0.01 | -0.16 | -0.12 | -0.12 | -0.07 | -0.09 | -0.11 | -0.63 | -0.06 | -0.48 | 0.00 | -0.45 | -0.44 |
| R&D Expense | 150.18K | 91.26K | 136.79K | 140.18K | 195.71K | 182.09K | 184.63K | 157.99K | 230.21K | 185.27K | 224.25K | 300.96K | 256.72K | 288.58K | 272.44K | 353.56K | 391.78K | 381.40K | 497.10K | 370.47K | 404.85K | 473.28K | 711.50K | 616.56K | 563.97K | 381.54K | 547.93K | 387.10K | 361.00K | 462.00K | 392.00K | 472.00K | 412.00K | 343.00K | 297.00K | 257.00K | 217.00K | 212.00K | 193.00K | 178.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.90M | 6.08M | 6.47M | 5.12M | 4.96M | 5.14M | 5.79M | 5.56M | 5.20M | 6.69M | 7.20M | 18.87M | 5.34M | 5.42M | 5.31M |
| Gross Profit | 1.53M | 2.30M | 2.43M | 1.67M | 1.54M | 1.52M | 2.02M | 1.75M | 1.29M | 1.78M | 366.29K | 2.98M | 446.00K | 611.00K | 498.00K |
| Operating Income | -132.26K | 505.00K | 514.01K | -446.59K | -670.60K | -826.95K | -954.63K | -1.48M | -2.41M | -2.40M | -7.50M | -4.53M | -7.22M | -6.37M | -5.14M |
| Net Income | 157.45K | 548.43K | 536.96K | -215.66K | -331.41K | -1.50M | -908.56K | -1.47M | -2.39M | -2.34M | -7.45M | -4.53M | -7.14M | -5.98M | -4.97M |
| Diluted EPS | 0.02 | 0.08 | 0.07 | -0.03 | -0.04 | -0.20 | -0.11 | -0.17 | -0.26 | -0.23 | -0.62 | -0.36 | -0.50 | -2.84 | -2.16 |
| R&D Expense | 420.57K | 347.13K | 459.09K | 589.87K | 733.64K | 780.33K | 1.13M | 1.40M | 1.68M | 1.91M | 2.19M | 1.81M | 1.58M | 1.49M | 1.02M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.96M | 5.57M | 6.39M | 6.47M | 6.12M | 5.73M | 5.02M | 5.22M | 5.25M | 17.26M | 11.82M | 11.37M | 14.45M | 9.25M | 5.95M |
| Total Equity | 4.06M | 4.33M | 4.98M | 5.83M | 5.91M | 5.60M | 5.22M | 4.49M | 4.33M | 3.98M | 14.21M | 9.23M | 8.32M | 11.72M | 6.59M | 4.11M |
| Cash & Equivalents | 1.06M | 989.27K | 1.08M | 2.47M | 1.51M | 1.09M | 1.89M | 1.23M | 1.20M | 686.78K | 8.64M | 4.20M | 5.92M | 9.72M | 4.17M | 2.40M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 1.26M | 3.05M | 2.59M | 3.05M | 2.73M | 2.66M | 1.84M |
| Current Liabilities | - | 625.01K | 592.29K | 559.89K | 555.84K | 523.93K | 506.03K | 528.87K | 896.81K | 1.26M | 1.48M | 1.30M | 2.01M | 1.95M | 2.20M | 1.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 328.80K | 147.41K | 1.39M | -862.27K | -405.48K | -208.78K | -722.86K | -1.17M | -2.24M | -4.30M | -5.25M | -479.00K | -5.47M | -5.36M | -3.84M |
| Investing Cash Flow | -431.68K | -113.17K | -257.12K | -282.53K | -22.78K | -95.19K | -96.08K | -130.35K | -171.11K | -118.93K | -295.58K | -170.00K | -78.00K | -115.00K | -37.00K |
| Financing Cash Flow | 37.89K | 55.40K | 258.51K | 185.28K | 9.56K | 1.11M | 157.73K | 1.29M | 1.91M | 12.37M | 1.11M | 2.39M | 9.39M | -81.00K | 2.11M |
| Capital Expenditure | -141.08K | -164.80K | -257.12K | -137.23K | -10.50K | -91.56K | -96.08K | -130.35K | -101.14K | -33.61K | -135.86K | -57.00K | -64.00K | -51.00K | - |
| Free Cash Flow | 187.72K | -17.39K | 1.14M | -999.51K | -415.98K | -300.34K | -818.94K | -1.30M | -2.35M | -4.33M | -5.39M | -536.00K | -5.54M | -5.41M | - |
Ratios (Annual)
Figures in %.
| Metric | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 31.1% | 37.8% | 37.5% | 32.6% | 31.1% | 29.7% | 34.9% | 31.5% | 24.8% | 26.6% | 5.1% | 15.8% | 8.4% | 11.3% | 9.4% |
| Operating Margin % | -2.7% | 8.3% | 7.9% | -8.7% | -13.5% | -16.1% | -16.5% | -26.6% | -46.4% | -35.9% | -104.2% | -24.0% | -135.3% | -117.6% | -96.7% |
| Net Margin % | 3.2% | 9.0% | 8.3% | -4.2% | -6.7% | -29.2% | -15.7% | -26.3% | -46.0% | -34.9% | -103.4% | -24.0% | -133.7% | -110.4% | -93.6% |
| ROE % | 3.6% | 11.0% | 9.2% | -3.6% | -5.9% | -28.7% | -20.2% | -33.9% | -60.1% | -16.5% | -80.7% | -54.4% | -60.9% | -90.7% | -121.1% |
| ROCE % | -3.1% | 10.1% | 8.8% | -7.6% | -12.0% | -15.8% | -21.3% | -34.3% | -60.6% | -15.2% | -71.3% | -48.4% | -57.7% | -90.3% | -122.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 0.57% | 26.37K | $66.20K |
| 2 | Geode Capital Management, LLC | 0.53% | 24.35K | $61.11K |
| 3 | Blackrock Inc. | 0.41% | 18.64K | $46.78K |
| 4 | Vanguard Capital Management LLC | 0.32% | 14.51K | $36.43K |
| 5 | Jane Street Group, LLC | 0.28% | 12.64K | $31.73K |
| 6 | LPL Financial LLC | 0.24% | 10.85K | $27.23K |
| 7 | UBS Group AG | 0.15% | 6.95K | $17.45K |
| 8 | Vanguard Fiduciary Trust Co | 0.14% | 6.61K | $16.60K |
| 9 | NewEdge Advisors, LLC | 0.08% | 3.60K | $9.04K |
| 10 | Tower Research Capital LLC (TRC) | 0.01% | 238 | $597 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMRA
Biomerica (BMRA) finance chief discloses four stock option awards - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQaENHZ1VBQWhDblFzOVU0cU9xZ2JuTFNKc3EwMHJuczh4X0pWY2RxMmNzT3dhQjlPUjRoZGpZZVQ2RWdBc0FQTVVEcW5GODlGdmVzUXhHUXE3M1pDMmhJVXdEbjlpV2U0dkVWNjNfMHNvdmozbFlQY0hiYzcxSG10Q19DT3dGNnIwOWNVQ2…
Biomerica director Gary M. Huff acquires $50,000 in BMRA stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbHJNanhDU19GekUwZjN2UlRJZW45ZnlwQmFXZDB1ZEZaaTN2NjRwWGp5eUdRUEZhUkNNZDRienR1cngzY0tsbnRHYzJzTkdWaHdTSlQ2dlFpTHFzemNjQm04Z09Cck1qeU1WN0pwdW95enV3U2VJT0x1bzNDTFg0RnVrYUo4cmJKb3JWSV…
BRC Group Holdings, Inc. Buys Biomerica Inc (BMRA) -- Shares Look 12% Overvalued on GF Value - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxON3pHTEFLbGZ5M3pUUUMybUNwSEJLcmJmUHhVUjdGVDdMVWpGS1NtTU1admFRMXRSdUFIRzhjdmRuS1BiMkpWY0xaZVhjc2ZKaEt4ckNtY1lpVTgtUmh1X0ZPRjRhYVN5eHc5ZmYtYk5RTzlPNnpUcjB4Q0x3OFZJUVFPX1pFNGpYZHQwOH…
BMRA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9NTXo0WDlpWGNVY1VBOWJDTFJaN1VkaGJXZFRBRGI2YmxzcmZrR0V6WTh4ck0yb29zYS1zOVRkRThaMTdmOUE?oc=5" target="_blank">BMRA</a> <font color="#6f6f6f">Finviz</font>…
Biomerica Announces $2.23 Million Private Placement at $1.60 per Share and Engages B. Riley to Review Strategic Alternatives - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxNRGhSdDBLTGtNVzFPbjZ1aGpNYS16ZWF2YXlZak1jRl9uZW1HOE5OdDI5SndsV2tWVEFlTWE5MkR1Y2JMVWxuYVUyeXdkaGdCZUhRMG5kd0NyME4yaGRmemJIaHJQUHFUNHI5SEotSUszWXFiN0tGbzBFMXUwUlM5VkFxU2Zfb25oVkFHQj…
Biomerica (BMRA) director adds 6,250 shares in private deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOOVFXUzl3YkE0LTl1YXFQS0lENWQ1RUJ1YThibWY2V2ZPYUFSZTN1b1k0dzd2TzV6SWpHS1dTQXdYcDJSRURGQVhKajB0WmpYMlVubnZjelE4NERXWUs5b0ZfLUtoVUlCYU9vV1EtajEwaEhnTTNnWWMzMkdaM0xHeG1Ia3hoZmw5alducl…
BMRA — Frequently Asked Questions
What is the current share price of Biomerica, Inc. (BMRA)?
As of 2026-09-19 21:16 PDT, Biomerica, Inc. (BMRA) trades at $2.34 on NasdaqCM. Its 52-week range is $1.49 to $3.51.
What is the market capitalisation of BMRA?
Biomerica, Inc. (BMRA) has a market capitalisation of $10.74M on NasdaqCM.
What is the P/E ratio of BMRA?
BMRA trades at a trailing price-to-earnings (P/E) ratio of -1.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.75.
What is the return on equity (ROE) of BMRA?
BMRA has a return on equity (ROE) of -112.10%. Its return on capital employed (ROCE) is -122.16%.
Is BMRA a good stock to buy?
This page provides a data-driven analysis of Biomerica, Inc. (BMRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.